Bharat Biotech to begin Vaccine Production by June 2022

Bharat Biotech to begin Vaccine Production

Bharat Biotech International Ltd (BBIL), the developer of Covaxin, is expected to begin production at its Andharua unit near Bhubaneswar by June 2022. The state government has issued the required statutory permissions and clearances to set up the new facility that will incur Rs 300 crore.


The Hyderabad-based company will roll out 10 types of vaccines, including Covaxin at the new unit. BBIL’s vaccines include malaria, Japanese encephalitis, rotavirus, pandemic influenza and drug-resistant staphylococcus aureus, and rabies.

Also read: Bharat Biotech: Maximum Price for Covaxin required to Recover Costs

Suresh Mahapatra, Odisha Chief Secretary, directed the state government officials to speed up the construction for starting the production by June next year during an E-meeting of state-level biotech implementation committee.


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top